cyrilzakka/clinical-trials huggingface dataset:
Clinical Trial of YuWell YE900 Electronic Sphygmomanometer

The purpose of this study is to evaluate the accuracy of the YuWell YE900 medical electronic blood pressure monitor for blood pressure measurements in adults and children according to the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Universal Standard (ISO 81060-2:2018).


Eligibility Criteria:
Inclusion Criteria:

1. 3 Years and older (Child, Adult, Older Adult);
2. Subjects voluntarily participate in the clinical trial and sign the informed consent.

Exclusion Criteria:

1. Disturbance of consciousness;
2. Patients requiring hemodialysis;
3. Taking anticoagulant drugs due to cardiovascular and cerebrovascular diseases;
4. Pregnant and lactating women;
5. Patients with cardiac arrhythmias;
6. Other conditions that the investigator considers ineligible for clinical trial.
Dilapan Versus Laminaria

This is a randomized, blinded clinical trial comparing overnight laminaria versus same-day Dilapan for cervical preparation for surgical abortions occurring between fourteen and eighteen weeks gestation. Comparisons will be made between procedure time, need for additional dilation, occurrence of complications, and patient and provider satisfaction.

Hypothesis:

Cervical preparation for surgical abortion, between fourteen and eighteen weeks gestation, with same-day Dilapan is non-inferior to cervical preparation with overnight laminaria within a five-minute difference.

Primary objective:

Determine differences in procedure times

Secondary objectives:

Examine complications, and need for additional dilation between early second-trimester surgical abortions performed after cervical preparation with same-day Dilapan versus those performed after cervical preparation with overnight laminaria


Eligibility Criteria:
Inclusion Criteria:

* Pregnancy between fourteen and eighteen weeks gestation
* Request for elective abortion and certainty of decision to proceed

Exclusion Criteria:

* Incarceration
* Minor status (women younger than eighteen years)
* Allergy to Dilapan or laminaria
* Inability to speak and understand Spanish or English
Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia

The purpose of this study is to demonstrate superior efficacy of sustained release quetiapine compared to placebo in patients with schizophrenia after receiving treatment for up to 6 weeks.


Eligibility Criteria:
Inclusion Criteria:

* Patient is able to provide written informed consent before beginning any study related procedures
* Patient has a documented clinical diagnosis of schizophrenia
* Patient is able to understand and comply with the requirements of the study, as judged by a study investigator

Exclusion Criteria:

* Patients with a history of non-compliance as judged by the study investigator
* Patients with a known lack of response to previous treatment with quetiapine
* Patients who have participated in another drug study within 4 weeks prior to enrollment into this study
* Patients who have previously participated in this study or study D1444C00132
Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations

This is a randomized controlled trial, examining the effects of a computerized, internet-based Cognitive Behavioral Therapy (CBT) Intervention for persons with a schizophrenia spectrum disorder who experience distressing auditory hallucinations (voices). Participants are randomized to one of two conditions: either to receive the 10-session computer-based program on a weekly basis, or to their usual care at their mental health clinic. This study takes place at Cambridge Health Alliance in Cambridge Massachusetts. It is hypothesized that the participants who participate in the CBT program will have significant improvements in the severity of their auditory hallucinations, as well as their associated distress, compared to the participants receiving usual care.


Eligibility Criteria:
Inclusion Criteria:

* Participants will be on a stable dose of antipsychotic medication for the past 3 months.

  * Schizophrenia-spectrum diagnosis, including schizophrenia, schizoaffective disorder, schizophreniform disorder, and psychosis, not otherwise specified.
  * At least moderate severity on Brief Psychiatric Rating Scale (BPRS) hallucinations item.
  * Naïve to CBTp for Auditory Hallucinations within the past 3 years.
  * No current suicidal ideation or hospitalization within the past month.
  * Reading level of at least 4th grade, as measured by the reading section of the Wide Range Achievement Test (WRAT)
  * Current patient receiving care at Cambridge Health Alliance

Exclusion Criteria:

* Terminal physical illness expected to result in the death of the study participant within one year.

  * Primary diagnosis of dementia or a diagnosis of a psychiatric disorder secondary to a medical condition.
  * Comorbid dementia (severe cognitive impairment) as indicated by a Mini-mental state examination score \<24.
  * Current active substance abuse or dependence with the need for specialized substance abuse services
  * Does not speak English
  * Does not achieve a 4th grade reading level as demonstrated on the Wide Range Achievement Test (WRAT)
  * Has a legal guardian
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

This is a non-therapeutic study design. After successful screening, subjects will be monitored for potential gene therapy-related adverse events for up to 15 years post MB-CART2019.1 infusion. Subjects will be assessed yearly for the occurrence of delayed adverse events (AEs), monitored for replication competent lentivirus (RCL) and assessed for long term efficacy as well as CAR-T persistence.

Eligibility Criteria:
Inclusion Criteria:

* Received zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study and have either completed the study or have discontinued early from the study.
* Provided written informed consent to participate in this study.

Exclusion Criteria:

* None
Establishing Normal Values for Neuropsychological Testing in HIV-negative Thais

The purpose of this study is to establish normal values for neuropsychological testing in HIV negative Thais stratified by age (1 decade) and education (no certificate or primary school certificate, less than high school certificate or vocational certificate, high school certificate or higher vocational certificate or diploma, Bachelor degree or higher.

The Southeast Asia Research Collaboration with Hawaii (SEARCH) operates or collaborates on several neuroAIDS research protocols. To allow accurate interpretation of neuropsychological data, normative data that are obtained in a similar population are needed. Currently, there are limited such data available for this purpose.

The SEARCH 001 study evaluated the neurocognitive changes before and after highly active antiretroviral therapy in 30 HIV positive subjects and has also enrolled 230/300 proposed HIV-negative controls for this purpose. Normative data tables typically require many more individuals so that age and education strata can be established. We now propose to enroll up to 1000 HIV-seronegative individuals for this purpose.

Eligibility Criteria:
Inclusion Criteria:

1. Age 20-69
2. Male or female
3. Negative HIV antibody at screening
4. Have the ability to understand the study and signed the informed consent form

Exclusion Criteria:

1. Head injury with loss of consciousness greater than 1 hour
2. Current or past illicit drug use or positive drug screen for amphetamine, methamphetamines, cocaine, marijuana, or narcotics
3. Severe illness within 30 days prior to entry
4. Current or recent fevers or meningeal signs.
5. History of pre-existing neurologic disease to include stroke, multiple sclerosis or autoimmune disease.
6. active major depression will be excluded as well - patients with past depression that is controlled and patients with or minor depressive symptoms will be allowed to enroll.
7. Known learning disability including dyslexia
8. Confusion or other signs and symptoms of metabolic encephalopathy or delirium
9. Focal neurological deficit on examination
10. Examining physician's concern that participant may not be able to complete visit requirements.
ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

Study of early administration of ASTX727 associated with late Donor Lymphocyte Infusions after allogenic stem cell transplantation in very high risk MDS or AML patients

Prospective study of early administration of ASTX727 associated with late Donor Lymphocyte Infusions after allogenic stem cell transplantation in very high risk MDS or AML patients

Eligibility Criteria:
Inclusion Criteria:

* Patients aged from 18 to 70 years
* MDS or AML with unfavorable genetics defined as follow:
* 4 or more cytogenetic abnormalities or
* 3 cytogenetic abnormalities and TP53 or other unfavorable mutations (ASXL1, RUNX1) or
* 3 cytogenetic abnormalities and monosomal karyotype or
* mutations involving EVI1
* AML patients should have received chemotherapy
* Marrow blast \< 20% for MDS and \< 10% for AML post chemotherapy
* For MDS : Revised IPSS poor or very poor ; For AML : ELN adverse risk
* Non-proliferative disease
* A donor is available (HLA matched or mismatched)
* Adequate contraception in women \< 50 years and for men. Subjects must agree to use, and to be able to comply with, effective contraception without interruption, at least the first six months after transplant, throughout the entire duration of study drug therapy and for at least 6 months for women and 3 months for men after the last dose of study drug therapy.

Exclusion Criteria:

* ECOG 3 or more
* Cancer less than 2 years before inclusion or cancer not in remission the last 2 years before inclusion (except in situ cancer or baso cellular cancer)
* Cardiac failure with Ejection Fraction \< 50%
* Creatininemia level \> 150 µmol/L
* Liver enzyme \> 3 N
* Conjugated bilirubinemia \> 25 µmol/L
* MDS occurring in patients with Fanconi anemia or congenital dyskeratosis
* Proliferative disease in patients not in remission: White Blood Cell (WBC) \> 15 G/L or use of continuous cytotoxic to maintain WBC \< 15 G/L
* AML with marrow or peripheral blast count higher than 10% after chemotherapy
* Known allergy or hypersensitivity to the investigational agent or decitabine or its metabolites or formulation excipients
* No contraception
* Pregnant or breastfeeding women
Physiological Changes With SPG Stimulation in Migraine Patients

Hypothesis:

Stimulation of the SPG at low frequencies (20 Hz)is believed to cause a physiological parasympathetic upregulation which increases VMCA, concentration and cephalic vessel diameter.


Eligibility Criteria:
Inclusion Criteria:

* Chronic migraine patients

Exclusion Criteria:

-
Energy Metabolism in Branched-chain Organic Acidemias

Energy metabolism and insulin sensitivity were assessed in a case-control study in patients with branched-chain organic acidemias.

Children and adults with branched-chain organic acidemias and matched healthy humans underwent deep metabolic phenotyping using non-invasive magnetic resonance spectroscopy, oral glucose tolerance tests and measurements of leucocyte respirometry in order to assess changes in energy metabolism and insulin sensitivity.

Eligibility Criteria:
Inclusion Criteria:

* known branched-chain organic acidemia diagnosed by enzymatic or genetic test
* age\>5 years

Exclusion Criteria:

* acute inflammatory conditions with fever, cold symptoms, gastro-intestinal infection within the last 24 hours
* contraindications for an oral glucose tolerance test such as fasting blood glucose \>126 mg/dl, severe chronic gastrointestinal conditions, allergy against black currant
* contraindications for magnetic resonance tomography (MRT) such as claustrophobia, metallic implants which are not MRT compatible
Randomized Controlled Trial of eScreen for Problematic Alcohol Use

Objectives: This study compares the efficacy of eScreen and Alkoholhjalpen in a three-armed randomized controlled design, measuring outcomes in terms of changes in problematic alcohol use up to one year after study recruitment. The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels. A more extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.

Method: Participants with problematic alcohol use (AUDIT \>7 for men and \>5 for women) are randomized into one of three groups: T1, eScreen referral (n=211); T2, Alkoholhjalpen referral (n=211); Control group (n=211). Outcomes on alcohol use as well as health-related symptoms are assessed after 3, 6 and 12 months.

The first hypothesis is that all three groups will reduce their alcohol consumption and alcohol-related problems at follow-ups compared to the baseline level. The second hypothesis is that there will be no differences between participants in the eScreen and the Alkoholhjalpen group in reduction of alcohol consumption and alcohol-related problems at follow-ups. The third hypothesis is that participants in the eScreen and the Alkoholhjalpen group will show a greater reduction in alcohol consumption and alcohol-related problems compared to the control group (no intervention) at follow-ups. For a greater understanding of the study results possible other interventions received by the study participants for their problematic alcohol use during these 12 months of study participation will be investigated.


Eligibility Criteria:
Inclusion Criteria:

* Problematic alcohol use. AUDIT\>7 for men and AUDIT\>5 for women

Exclusion Criteria:

* Drug use DUDIT\>0
* Unproblematic alcohol use, AUDIT\<8 for men and AUDIT\<6 for women
High Intensity Resistance Training With and Without Blood Flow Restriction in ACL Reconstruction

This study is randomized and single-blinded. Ethical approval is taken from the ethical committee of riphah international university, Lahore. Participants who meet the inclusion criteria will be enrolled in Groups A \& B through the sealed envelop method by the Non-Probability Convenient random sampling technique. Group A will perform traditional High-intensity resistance training without Blood Flow Restriction training after ACL Reconstruction Surgery. Group B will perform traditional High-intensity Resistance training with Blood Flow Restriction training after ACL Reconstruction Surgery.

The objective of the study is to determine the effects of high-intensity resistance training with and without blood flow restriction on quadriceps strength, power, and agility after ACL reconstruction among volleyball players. This study is randomized and single-blinded. Ethical approval is taken from the ethical committee of riphah international university, Lahore. Participants who meet the inclusion criteria will be enrolled in Groups A \& B through the sealed envelop method by the Non-Probability Convenient random sampling technique. Group A will perform traditional High-intensity resistance training without Blood Flow Restriction training after ACL Reconstruction Surgery. Group B will perform traditional High-intensity Resistance training with Blood Flow Restriction training after ACL Reconstruction Surgery. The outcome measures will be assessed by hand held dynamometer.1-RM test, Illinois Agility Test, and Vertical jump test.

The data will be analyzed by SPSS,version 25.Statistical siginificance is P= 0.05.

Eligibility Criteria:
Inclusion Criteria:

* Male players with age group 18 to 25 years,Return to function phase of rehabilitation,Players with Grade III ACL Tear ,Athletes who have been playing for at least 2 years

Exclusion Criteria:

* Players after ACL Reconstruction in acute or subacute phase,Players with other biomechanical issues of knee or feet,Players with any hematological disorders or hypertension
Genentech Validation Tool for Pulmonary Fibrosis

Radiology is an important component of the multidisciplinary team. The primary goal of this project will be to create a tool using findings on chest computed tomography (CT) for nearly 300 patients with the most common types of fibrosis. The tool will be tested using chest CT scans of an additional 100 patients with the 3 most common diagnoses of fibrosis. The second objective will be to further validate the tool by performing a reader study with 3 co-investigating radiologists and ask them to look at 100 CT scans of patients with fibrosis without tool and then with tool and see if accuracy of diagnosis improves compared to the working diagnosis when using the tool.


Eligibility Criteria:
Inclusion Criteria:

* Retrospective review of adults (age \> 21) with diagnosis of pulmonary fibrosis on chest CT and a pulmonologist report in electronic medical record confirming the working diagnosis from 1/1/2010 through 7/1/2019.

Exclusion Criteria:

* Failure to meet inclusion criteria including age \< 21 and lack of a pulmonologists report in the medical record with a working diagnosis of patient's type of pulmonary fibrosis.
Effects of Swedish Massage Prior Circuit Breathing Training on Asthma

The objective of this study was to determine the effects of Swedish massage prior circuit breathing training on asthma control and respiratory function in patients with asthma.

Thirty patients with asthma aged 20-65 years were randomized into 3 groups: the control group (CON; n=10), the Circuit Breathing Training group (CBT; n=10), and the Swedish Massage prior to Circuit Breathing Training group (SBT; n=10). Participants in the CON group carried out their daily routine without receiving any training program. The CBT group received circuit breathing training sessions lasting thirty minutes each, three times a week for twelve weeks, while the SBT group received a Swedish massage (20 minutes) before circuit breathing exercises (30 minutes) three times a week for twelve weeks. Physiological data, pulmonary function, respiratory muscle strength, cytokine levels, Asthma Control Test scores, Visual Analogue Scale scores, chest expansion, and muscle flexibility variables were analyzed during the pre-test, post-test at 6 weeks, and post-tests at 12 weeks. Two-way repeated measures ANOVA was used to compare the variables between each test and between groups. Statistical significance was defined as p \< .05.

Eligibility Criteria:
Inclusion Criteria:

* Being a male or female patient with asthma who is between 20 and 65 years old.
* Being a patient who has been diagnosed by a doctor with asthma for at least 6 months.
* The severity of the disease has been assessed at levels 2 to 4, meaning the volume of air expelled in the first second of breathing quickly and with full force (Forced Expiratory Volume in one second; FEV1) is between 80% and 30% on the date of data collection. This has been certified by a doctor, and the patient is using medication according to the normal treatment plan.
* Must not have other respiratory diseases such as tuberculosis, lung cancer, emphysema, chronic obstructive pulmonary disease (COPD), etc.
* Should not have received exercise training for more than 20 minutes at a time, 3 days/week, or more in the past 6 months before participating in the research.
* Having no communication problems.
* The sample volunteers to participate in the research and agrees to sign the consent form to participate in the research.

Exclusion Criteria:

* Being a patient who has a history of asthma caused by exercise (Exercise-Induced Asthma).
* In case of a force majeure event that makes it impossible to continue participating in the research, such as injury from an accident or illness, etc.
* Participating in less than 80 percent of the training sessions (28 times out of 36 times) for the breathing training group and the group that practiced breathing together with massage.
* Unwillingness to continue participating in the research.
Pleth Variability Index in Pulmonary Embolism

Pulmonary embolism(PE) is a ventilation/perfusion disorder caused by obstruction of the pulmonary artery, usually by a thrombus. The Pleth Variability Index(PVI) is a continuous, noninvasive indicator of dynamic perfusion index changes in photoplethysmography that occur in at least one respiratory cycle. The aim of this study is to evaluate the prognostic and mortality indicator role of PVI in patients with PE, hypothesizing that PVI could serve as a valuable guide in this disease where perfusion impairment is fundamental.

Based on our study, we determined that PVI could be a non-invasive, rapid, and objective tool for predicting disease progression and mortality in PE patients in the emergency department. Our study is the first to evaluate the PVI in PE.

Pulmonary embolism(PE) is a ventilation/perfusion disorder caused by obstruction of the pulmonary artery, usually by a thrombus. The Pleth Variability Index(PVI) is a continuous, noninvasive indicator of dynamic perfusion index(PI) changes in photoplethysmography that occur in at least one respiratory cycle. The aim of this study is to evaluate the prognostic and mortality indicator role of PVI in patients with PE, hypothesizing that PVI could serve as a valuable guide in this disease where perfusion impairment is fundamental.

In the emergency department, data were recorded for patients over 18 years of age diagnosed with pulmonary embolism, demographic data, risk scores and measurements. PVI and PI values were analyzed across different scoring systems, hospitalization statuses, and mortality groups. A survival analysis was conducted to evaluate the impact of PVI and PI on 1-year mortality in patients. The study was assessed with the STROBE checklist.

A total of 49 patients were included in this prospective, single-center study. The PVI value was significantly higher, whereas the PI value was significantly lower in the exitus group compared to the living group (p=0.027, p=0.011). The area under the curve values for PVI, pulmonary embolism severity index (PESI) score, and PI were determined to be 0.714, 0.820, and 0.745, respectively. It was observed that the negative predictive value of PESI was 100%, while the positive predictive value of PVI was the highest at 53.5%. In the. The mean survival time was significantly shorter for patients with PVI \>40 and PI \<1.9 (p=0.001, p=0.002). An increase in PVI was associated with a 4.04-fold increase in the risk of death (HR: 5.04, 95% CI: 1.50-16.92, p=0.009).

PVI can be considered a noninvasive, rapid, and objective tool for predicting the course and mortality of the disease in PE patients in the emergency department. Our study is the first to evaluate the PVI in PE.

Eligibility Criteria:
Inclusion Criteria:

* To be over 18 years old
* Diagnosis of pulmonary embolism

Exclusion Criteria:

* patients had asthma and chronic obstructive pulmonary disease exacerbation
* patients had acute decompensated heart failure
* patients were pregnant
* patient was under 18 years old